| 000 | 00705nam a22002172 4500 | ||
|---|---|---|---|
| 001 | hsl001007267 | ||
| 003 | DGPO | ||
| 005 | 20170826152558.0 | ||
| 008 | 170117s1975 dcu f000 0 eng d | ||
| 040 |
_aGPO _cGPO _dMvI |
||
| 086 | 0 | _aHE 20.3161/A:R 118/4 | |
| 099 | _aHE 20.3161/A:R 118/4 | ||
| 245 | 0 | 0 | _aSerum levels of N2,N2 dimethylguanosine and pseudouridine as determined by radioimmunoassay for patents [sic] with malignancy. |
| 260 |
_a[Washington, D.C., _c1975] |
||
| 300 | _av. | ||
| 490 | 0 | _aBrief communication | |
| 500 | _aReprinted from JNCI 54,2. | ||
| 500 | _aCRDP Program Historic Shelflist record. | ||
| 650 | 0 |
_aCancer _xResearch. |
|
| 710 | 2 | _aNational Cancer Institute (U.S.) | |
| 949 |
_aBEV _bFed Docs |
||
| 999 |
_c264682 _d264682 |
||